Clinical trials: Sensory Disorders

Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS)

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

• No Longer Available
• Age: 2 years and older
• Expanded access
• Pill or oral medicine

ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical…

Conditions

Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders

Trial name

NCT03317366

Testing

ARQ 092

Sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)